Ocular Therapeutix
OCUL
118 hedge funds and large institutions have $330M invested in Ocular Therapeutix in 2023 Q4 according to their latest regulatory filings, with 26 funds opening new positions, 38 increasing their positions, 30 reducing their positions, and 21 closing their positions.
160% more capital invested
Capital invested by funds: $127M → $330M (+$203M)
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
27% more repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 30
24% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 21
16.26% more ownership
Funds ownership: 50.91% → 67.17% (+16%)
4% more funds holding
Funds holding: 113 → 118 (+5)
23% less call options, than puts
Call options by funds: $1M | Put options by funds: $1.3M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$27.3M |
| 2 |
VA
VR Adviser
New York
|
+$23M |
| 3 |
Franklin Resources
San Mateo,
California
|
+$13.3M |
| 4 |
LGM
Logos Global Management
San Francisco,
California
|
+$11.8M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$6.64M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$3.04M |
| 2 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$1.18M |
| 3 |
ECM
Endurant Capital Management
San Mateo,
California
|
-$1.11M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
-$958K |
| 5 |
PAMP
Polar Asset Management Partners
Toronto,
Ontario, Canada
|
-$828K |
OCUL Hedge Fund Activity: Q4 2023 in Review
118 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Ocular Therapeutix (OCUL) for Q4 2023, worth a combined $330M — up 160% from $127M a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new OCUL positions and 21 closed out — a net gain of 5 holders — while 38 added to existing stakes and 30 trimmed.
The largest buyer was Deep Track Capital, opening a new position worth an estimated $27.3M. The largest seller was Sectoral Asset Management, exiting entirely with an estimated $3.04M sold.
- 118 institutional investors held Ocular Therapeutix (OCUL) as of Q4 2023, up from 113 in Q3 2023.
- Funds reported $330M of Ocular Therapeutix stock for Q4 2023, up 160% quarter-over-quarter.
- 26 funds opened new Ocular Therapeutix positions in Q4 2023 and 21 closed out, a net change of +5 holders.
- The largest Ocular Therapeutix buyer in Q4 2023 was Deep Track Capital, an estimated $27.3M added.
- The largest Ocular Therapeutix seller in Q4 2023 was Sectoral Asset Management, an estimated $3.04M sold.
Based on aggregated 13F filings for Q4 2023.